Jason Ferrone
Fondatore presso Intrinsic Medicine, Inc.
Posizioni attive di Jason Ferrone
Società | Posizione | Inizio | Fine |
---|---|---|---|
Intrinsic Medicine, Inc.
Intrinsic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Intrinsic Medicine, Inc. operates as a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. The company was founded by Alexander Martinez and Jason Ferrone in August, 2018 and is headquartered in Seattle, WA. | Direttore/Membro del Consiglio | 01/08/2018 | - |
Fondatore | 01/08/2018 | - | |
Direttore operativo | 01/08/2018 | - | |
Presidente | 01/08/2018 | - | |
Creyon Bio, Inc.
Creyon Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Creyon Bio, Inc. is a pre-clinical stage drug development company based in San Diego, CA. The company is focused on developing precision oligonucleotide-based medicines (OBMs) such as ASOs, siRNAs, guide RNAs, RNA editing guides, mRNAs, and aptamers. Creyon Bio uses a data-first approach to generate powerful datasets and develop machine learning models to uncover the engineering principles that make precision OBMs possible for patient populations of all sizes. The CEO of the company is Christopher E Hart. | Direttore operativo | 20/07/2023 | - |
Consigliere Generale | 20/07/2023 | - |
Storia della carriera di Jason Ferrone
Precedenti posizioni note di Jason Ferrone
Società | Posizione | Inizio | Fine |
---|---|---|---|
IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2007 | 01/04/2018 |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | - |
Formazione di Jason Ferrone
Suffolk University Law School | Graduate Degree |
San Diego State University | Graduate Degree |
University of California, Riverside | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Chief Operating Officer | 2 |
Corporate Officer/Principal | 2 |
Graduate Degree | 2 |
Settori
Consumer Services | 4 |
Commercial Services | 3 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Intrinsic Medicine, Inc.
Intrinsic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Intrinsic Medicine, Inc. operates as a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. The company was founded by Alexander Martinez and Jason Ferrone in August, 2018 and is headquartered in Seattle, WA. | Commercial Services |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
Creyon Bio, Inc.
Creyon Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Creyon Bio, Inc. is a pre-clinical stage drug development company based in San Diego, CA. The company is focused on developing precision oligonucleotide-based medicines (OBMs) such as ASOs, siRNAs, guide RNAs, RNA editing guides, mRNAs, and aptamers. Creyon Bio uses a data-first approach to generate powerful datasets and develop machine learning models to uncover the engineering principles that make precision OBMs possible for patient populations of all sizes. The CEO of the company is Christopher E Hart. | Commercial Services |
- Borsa valori
- Insiders
- Jason Ferrone
- Esperienza